Cystic fibrosis: NHS England strikes deal to offer triple combination treatment

被引：2
|
作者：
Iacobucci, Gareth
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 370卷
关键词：
D O I：
10.1136/bmj.m2643
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
    Sharma, Dolly
    Xing, Shan
    Hung, Yu-Ting
    Caskey, Rachel N.
    Dowell, Maria L.
    Touchette, Daniel R.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
  • [42] Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis
    Pilcer, Gabrielle
    De Bueger, Veronique
    Traina, Karl
    Traore, Hamidou
    Sebti, Thami
    Vanderbist, Francis
    Amighi, Karim
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 451 (1-2) : 112 - 120
  • [43] Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
    Dolly Sharma
    Shan Xing
    Yu-Ting Hung
    Rachel N. Caskey
    Maria L. Dowell
    Daniel R. Touchette
    [J]. Orphanet Journal of Rare Diseases, 13
  • [44] Treatment of vitamin K deficiency in cystic fibrosis: Effectiveness of a daily fat-soluble vitamin combination
    Wilson, DC
    Rashid, M
    Durie, PR
    Tsang, A
    Kalnins, D
    Andrew, M
    Corey, M
    Shin, J
    Tullis, E
    Pencharz, PB
    [J]. JOURNAL OF PEDIATRICS, 2001, 138 (06): : 851 - 855
  • [45] Effects of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy on Glycaemic Control and Body Composition in Patients with Cystic Fibrosis-Related Diabetes
    Grancini, Valeria
    Gramegna, Andrea
    Zazzeron, Laura
    Alicandro, Gianfranco
    Porcaro, Laura L.
    Piedepalumbo, Federica V.
    Lanfranchi, Chiara
    Dacco, Valeria
    Orsi, Emanuela
    [J]. DIABETES, 2023, 72
  • [46] Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
    Taylor-Cousar, Jennifer L.
    Mall, Marcus A.
    Ramsey, Bonnie W.
    McKone, Edward F.
    Tullis, Elizabeth
    Marigowda, Gautham
    McKee, Charlotte M.
    Waltz, David
    Moskowitz, Samuel M.
    Savage, Jessica
    Xuan, Fengjuan
    Rowe, Steven M.
    [J]. ERJ OPEN RESEARCH, 2019, 5 (02)
  • [47] Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
    Grancini, Valeria
    Gramegna, Andrea
    Zazzeron, Laura
    Alicandro, Gianfranco
    Porcaro, Laura L.
    Piedepalumbo, Federica
    Lanfranchi, Chiara
    Dacco, Valeria
    Orsi, Emanuela
    Blasi, Francesco
    [J]. DIABETES & METABOLISM, 2023, 49 (05)
  • [48] SERUM AND SPUTUM CONCENTRATIONS OF NETILMICIN IN COMBINATION WITH ACYLUREIDOPENICILLIN AND CEPHALOSPORINS IN CLINICAL TREATMENT OF PULMONARY EXACERBATIONS IN CYSTIC-FIBROSIS
    HJELTE, L
    MALMBORG, AS
    STRANDVIK, B
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (06) : 885 - 890
  • [49] Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis (vol 15, pg 1029, 2019)
    Shiferaw, D.
    Faruqi, S.
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1207 - 1207
  • [50] TARGETED LUNG DELIVERY BY INHALABLE MULTIFUNCTIONAL MICROPARTICULATE/NANOPARTICULATE AEROSOLS FOR CYSTIC FIBROSIS COMBINATION DRUG/MUCOLYTIC TREATMENT
    Li, X.
    Hayes, D.
    Mansour, H. M.
    [J]. PEDIATRIC PULMONOLOGY, 2011, : 346 - 346
12345